Rimonabant White Or Almost White Crystalline Powder A New Type Of Weight Loss Drug That Can Be Used To Quit Smoking

1. Product title: Rimonabant

2. Product parameter table:

3. Product introduction:(rimonabant) is the world's first type 1 cannabinoid receptor (CB1) inhibitor weight loss drug. It has a good weight loss effect, and has the effects of insulin sensitization and improvement of lipid metabolism disorders. It also has a certain effect of assisting smoking cessation. It was approved for marketing in the European Union in 2006 as a new weight-loss drug. However, some studies have shown that Rimonaban can increase serious mental adverse reactions, that is, depression and anxiety. FDA data indicates that Rimonaban can increase the risk of suicide among users.

4. Chemical and physical properties of Limonaban:Density 1.4±0.1 g/cm3
Boiling point 627.6ºC at 760 mmHg
Melting point 230-240ºC
Molecular formula C22H21Cl3N4O
Molecular weight 463.787
Flash point 333.3ºC
Accurate quality 462.078094
PSA 50.16000
LogP 6.01
Appearance: white or almost white crystalline powder
Refractive index 1.66

5. Pharmacological action:This product is a cannabinoid (CB1) receptor antagonist. CB1 receptors are part of the endocannabinoid system, which is responsible for the physiological regulation of food intake and appetite. There are CB1 and CB2 receptors in the endocannabinoid system. This product has no affinity for non-cannabinoid receptors. The affinity for CB1 receptors is 1000 times greater than that for CB2 receptors, and the affinity for CB1 receptors located in the center is greater than CB1 receptors located on the periphery. This product reduces the appetite and food intake by inhibiting the endocannabinoid system, thereby reducing weight. Animal experiments indicate that in addition to centrally regulating food intake, the endocannabinoid system can also act on the peripheral system to affect energy consumption and/or glucose and lipid metabolism. In addition, it is also responsible for processing cognitive and motor functions, and controlling nicotine dependence, fear and anxiety. This product may also act on the substantia nigra neurokinin-3 receptor by changing the activity of dopaminergic neurons, suggesting antipsychotic effects. However, controlled clinical trials have found that this product has no therapeutic effect on schizophrenia or schizoaffective mental disorder. [2]
Rimonaban works by blocking CB1 receptors. CB1 receptors are widely distributed in mammals and have high levels in the hypothalamus and limbic system. These two parts are the most important structures for controlling strengthening and food intake. Excessive food intake and external stimulation from nicotine can lead to excessive activity of the EC system. This will act on the hypothalamus to increase appetite, and act on the nucleus accumbens to increase the desire to eat or smoke, both of which can cause increased food intake and continued tobacco dependence. Rimonaban is a cannabinoid receptor (CB1) antagonist that reduces appetite and smoking cravings by blocking cannabinoid receptors in brain tissue. That is, while reducing weight, it can also let people quit dependence on nicotine in cigarettes, so as to achieve the effect of smoking cessation.

6. Product pictures :